MaaT-033 is under clinical development by MaaT Pharma and currently in Phase III for Axial Spondyloarthritis. According to GlobalData, Phase III drugs for Axial Spondyloarthritis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MaaT-033’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MaaT-033 overview

MaaT-033 is under development for the treatment of axial spondyloarthritis (SpA), amyotrophic lateral sclerosis, non-small cell lung cancer (NSCLC) ,chemotherapy effects in acute myeloid leukemia and myelodysplastic syndrome patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is administered by oral route as a capsule. The drug candidate comprises lyophilized biotherapeutic in a controlled-release capsule containing full-ecosystem microbiota pooled from healthy donors, butycore. The drug candidate is developed based on gutPrint AI platform MET-N technology.

MaaT Pharma overview

MaaT Pharma (MaaT) is a biotechnology company that develops novel treatments for Gut Microbiota dysbiosis related diseases. The product portfolio in clinical development including one in Phase II are MaaT013 for the treatment of acute graft-versus-host disease for the prevention of complications of allogeneic hematopoietic stem cell transplantation and in preclinical development and MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors. It develops treatment for infectious diseases related to onco-hematology in fragile patients. MaaT is headquartered in Lyon, France.

For a complete picture of MaaT-033’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.